METHODS: This retrospective observational cohort study involved patients receiving TNB (levobupivacaine, clonidine, corticosteroid) between 2014 and 2018 at a postoperative pain clinic in France. Change in QOL from Day 0 (before block) to Day 15 was assessed according to SF-12.
RESULTS: 21 patients (62 ± 14 y) were included in the study. Most patients (71%) were referred following surgery or dentistry. Of the 9 patients (43%) who exhibited >10% increase in SF-12 scores and so were deemed responders, SF12-physical and SF12-mental were increased by mean differences of 17 and 9 points, respectively. The mean duration of block lasted 15 ± 59 days (range 1 to 90 days) and no severe adverse effects were observed.
CONCLUSIONS: Improved QOL was observed in approximately 50% of patients with trigeminal neuralgia (TN) two weeks after specific nerve block. The technique was easy to administer and well accepted by the patients.
方法:这项回顾性观察性队列研究涉及接受TNB(左旋布比卡因,可乐定,皮质类固醇)2014年至2018年在法国的术后疼痛诊所。根据SF-12评估从第0天(阻断前)到第15天的QOL变化。
结果:21例(62±14岁)患者被纳入研究。大多数患者(71%)在手术或牙科后转诊。在9名患者(43%)中,SF-12评分增加>10%,因此被视为响应者,SF12-身体和SF12-精神分别增加了17和9分的平均差异,分别。阻断的平均持续时间持续15±59天(范围1至90天),并且没有观察到严重的不良反应。
结论:在特定神经阻滞两周后,约有50%的三叉神经痛(TN)患者的生活质量得到改善。该技术易于使用,并被患者接受。